Omiloxetine (INN) is an antidepressant with a similar chemical structure to that of paroxetine which either was or is still under development by Ferrer for the treatment of major depression. It acts as a highly selective serotonin reuptake inhibitor (SSRI), and is said to possess a greater degree of selectivity for serotonin reuptake over dopamine and norepinephrine reuptake compared to other SSRIs. Though omiloxetine is listed as still under development on Ferrer's website, there has been no new news on the drug since late 2005.